Newsroom
Sorted by: Latest
-
Franklin Street Properties Corp. Announces Third Quarter 2026 Results
WAKEFIELD, Mass.--(BUSINESS WIRE)--Franklin Street Properties Corp. (the “Company”, “FSP”, “we” or “our”) (NYSE American: FSP), a real estate investment trust (REIT), announced its results for the third quarter ended September 30, 2026. George J. Carter, Chairman and Chief Executive Officer, commented as follows: “As we continue to move through 2026, our focus remains squarely on trying to maximize shareholder value through our expanded evaluation of strategic alternatives, proactive asset mana...
-
Essex Announces Third Quarter 2026 Results and Raises Full-Year 2026 Guidance
SAN MATEO, Calif.--(BUSINESS WIRE)--Essex Property Trust, Inc. (NYSE: ESS) (the “Company”) announced today its third quarter 2026 earnings results and related business activities. Net Income, Funds from Operations (“FFO”), and Core FFO per diluted share for the three and nine-month periods ended September 30, 2026 are detailed below. Three Months Ended September 30, Nine Months Ended September 30, % % 2026 2025 Change 2026 2025 Change Per Diluted Share Net Income $1.52 $2....
-
Riassunto: Pythia Labs lancia anticorpi progettati con l'IA per bersagli difficili da trattare farmacologicamente
LOS ANGELES e SAN DIEGO--(BUSINESS WIRE)--Pythia Labs, azienda biotecnologica che sviluppa modelli per l'IA di frontiera per la scoperta terapeutica, oggi ha annunciato il suo lancio assieme alla versione preprint pubblicata nell'archivio bioRxiv con cui ha presentato Pythia-1, il modello generativo a livello atomico che costituisce il fulcro della sua piattaforma di progettazione di anticorpi. La tecnologia di Pythia è stata sviluppata per creare anticorpi contro bersagli che hanno rappresenta...
-
Resumen: Pythia Labs se presenta en sociedad con anticuerpos diseñados por IA para dianas terapéuticas difíciles de abordar
LOS ÁNGELES y SAN DIEGO--(BUSINESS WIRE)--Pythia Labs, una empresa de biotecnología que desarrolla modelos de IA de frontera para el descubrimiento de terapias, anunció hoy su lanzamiento junto con un artículo preliminar en bioRxiv donde presenta Pythia-1, el modelo generativo de átomos completos que representa el núcleo de su plataforma de diseño de anticuerpos. La tecnología de Pythia está diseñada para crear anticuerpos contra dianas que han resultado difíciles de abordar con métodos convenc...
-
Samenvatting: Pythia Labs lanceert antilichamen ontwikkeld aan de hand van AI voor moeilijk te behandelen targets
LOS ANGELES & SAN DIEGO--(BUSINESS WIRE)--Pythia Labs, een biotechnologiebedrijf dat frontier AI-modellen voor therapeutische ontdekking samenstelt, kondigde vandaag de lancering aan, samen met een preprint in bioRxiv ter introductie van Pythia-1, het generatieve 'all-atom'-model dat centraal staat in zijn platform voor ontwerp van antilichamen. Pythia’s technologie is ontwikkeld om antilichamen te creëren tegen targets die voor conventioneel ontdekken een uitdaging bleken, waaronder multi-pass...
-
Pythia Labs startet mit KI-entwickelten Antikörpern gegen bislang schwer behandelbare Zielstrukturen
LOS ANGELES UND SAN DIEGO, Kalifornien, USA--(BUSINESS WIRE)--Pythia Labs, ein Biotechnologieunternehmen, das hochmoderne KI-Modelle für die Wirkstoffforschung entwickelt, hat seinen offiziellen Start bekannt gegeben und gleichzeitig einen Preprint zu Pythia-1 auf bioRxiv veröffentlicht. Das generative Modell arbeitet mit einer atomgenauen Darstellung und bildet das Herzstück der unternehmenseigenen Plattform zur Entwicklung von Antikörpern. Die Technologie von Pythia ermöglicht die Entwicklung...
-
Lancement de Pythia Labs avec des anticorps conçus par l’IA contre des cibles thérapeutiques difficiles à traiter
LOS ANGELES et SAN DIEGO--(BUSINESS WIRE)--Pythia Labs, une entreprise de biotechnologie développant des modèles d’IA de pointe destinés à la découverte thérapeutique, a annoncé aujourd’hui son lancement, accompagné de la publication d’une pré-publication sur la bio-archive bioRxiv présentant Pythia-1, le modèle génératif prenant en compte tous les atomes, qui constitue le cœur de sa plateforme de conception d’anticorps. La technologie de Pythia est conçue pour créer des anticorps ciblant des m...
-
SLB公布2026年第三季度业绩
休斯敦--(BUSINESS WIRE)--(美国商业资讯)-- SLB(NYSE:SLB)今日公布2026年第三季度业绩。 第三季度业绩 (除每股金额外,单位均为百万美元) 截至时间 变动 截至2026年9月30日止三个月 截至2026年6月30日止三个月 截至2025年9月30日止三个月 环比变动 同比变动 营收 $9,449 $8,972 $8,928 5% 6% 税前利润——GAAP口径 $1,019 $1,018 $1,000 0% 2% 税前利润率——GAAP口径 10.8% 11.4% 11.2% -57bps -42bps 归属于SLB的净利润——GAAP口径 $735 $786 $739 -6% -1% 摊薄每股收益——GAAP口径 $0.49 $0.52 $0.50 -6% -2% 调整后EBITDA* $2,067 $1,899 $2,061 9% - 调整后EBITDA利润率* 21.9% 21.2% 23.1% 71bps -121bps 分部税前营业利润* $1,576 $1,404 $1,626 12% -3%...
-
Hubio and EMC Insurance Partner to Modernize Workers’ Compensation Reporting on Guidewire Cloud
TORONTO--(BUSINESS WIRE)--Hubio and EMC Insurance partner to modernize Workers’ Compensation reporting on Guidewire Cloud with regul8, maintaining regulatory compliance....
-
TechnipFMC Declares Quarterly Dividend
NEWCASTLE & HOUSTON--(BUSINESS WIRE)--TechnipFMC plc (NYSE: FTI) today announced that its Board of Directors has authorized and declared a quarterly cash dividend of $0.05 per share, payable on December 2, 2026 to shareholders of record as of the close of business on the New York Stock Exchange on November 17, 2026, which is also the ex-dividend date. Important Information for Investors and Securityholders Forward-Looking Statement This release contains "forward-looking statements" as defined i...